Impact of Thrombosis and Bleeding in Patients with Severe COVID-19 versus Other Viral Pneumonias in the Context of Extracorporeal Membrane Oxygenation

Anna Weatherill,Mike Laffan,Mihaela Gasper,Paolo Bianchi,Maurizio Passariello,Suveer Singh,James Doyle,Brijesh Patel,Stephane Ledot,Benjamin Garfield,Deepa J. Arachchillage

DOI: https://doi.org/10.1055/s-0041-1732371

2021-08-13

Seminars in Thrombosis and Hemostasis

Abstract:Extracorporeal membrane oxygenation (ECMO) could be life saving for patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-induced severe respiratory failure not responding to optimal conventional management, including mechanical ventilation and proning.[1] However, thrombosis and/or bleeding may be major complications of patients supported with ECMO.[2] The aim of this single-center retrospective observational study in a UK ECMO center was to assess whether thrombotic or bleeding phenotypes differ in patients with severe coronavirus disease 2019 (COVID-19) pneumonia treated with veno-venous (VV)-ECMO compared to those who received VV-ECMO for other viral pneumonias. Mortality rate up to 120 days after VV-ECMO initiation was also assessed, as well as the factors directly contributing to death.Fifty-four consecutive COVID-19 patients supported with VV-ECMO from March 17th, 2020 to May 26th, 2020 were compared with an age and sex-comparable cohort of 43 patients with non-COVID-19 viral pneumonia from April 5th 2018 to January 19th, 2020. Of the 43 non-COVID-19 patients, the majority of them had Influenza A (38/43, 88.4%), 4.6% (2/43) had non-coronavirus disease 2019 (non-COVID-19), one patient had co-infection of parainfluenza and rhinovirus and the remaining two patients had human metapneumovirus and adenovirus, respectively. All patients had a confirmed diagnosis of viral infection from polymerase chain reaction nasopharyngeal swabs. Both cohorts were managed using the same scanning and anticoagulant protocols.[3] The study was approved by the Research Ethics Committee and the local Research and Development Office (reference number: 20/EE/0160).Anticoagulation with unfractionated heparin (UFH) was managed as described in our previous study.[3] Argatroban was used in patients with heparin-induced thrombocytopenia (HIT) or when heparin resistance was evident.[4] All thrombotic and bleeding complications were identified on routine or clinically indicated CT or ultrasound (US) imaging. Routine whole-body CT imaging was performed in all patients within 24 hours of admission for VV-ECMO. Routine upper and lower limb compression US and/or CT venography was performed within 24 hours of ECMO decannulation. Additional imaging was performed as indicated for clinical suspicion of thrombosis or bleeding.Bleeding events were defined as major or clinically relevant minor hemorrhages according to ISTH classification.[5] [6] Diagnosis of HIT was performed as described previously[3] (appendix page 1). Anticoagulant levels and target on the day of thrombotic or bleeding events were recorded.Results are presented as percentages for categorical data, median and range for skewed continuous data, and means (95% confidence interval). Groups were compared using the Chi-square test for categorical data, and the t-test for continuous data (as appropriate). p-Values <0.05 were considered statistically significant. Changes in blood results over time are presented in graphical format.Baseline characteristics of the COVID-19 and non-COVID-19 cohorts were comparable by age, sex, body-mass index (BMI), and co-morbidities ([Table 1]). The duration of VV-ECMO was greater in patients with COVID-19 compared to non-COVID-19: median (range) was 19 (3–57) days versus 15 (3–60) days (p = 0.02). Laboratory parameters (averaged in the first 24 hours after initiation of ECMO) are presented in [Table 1]. Platelet and neutrophil counts were higher in patients with COVID-19 compared to non-COVID-19. Median fibrinogen levels on admission were increased in both groups but were significantly higher in the COVID-19 cohort. There were no other laboratory parameter differences between groups in the 24 hours following initiation of ECMO.VariableReference rangeCOVID-19 (n = 54)Non-COVID-19 (n = 43)p-ValueAge, mean (SD)–46.3 (10.8)46.4 (10.5)0.96Gender, male–40 (74.1%)31 (72.1%)1.0BMI, mean (SD)–29.8 (6.4)30.4 (7.2)0.65Diabetes–11 (20.4%)11 (25.6%)0.61Ischemic heart disease–00–Hypertension–13 (24.1%)9 (20.9%)0.80Previous VTE–02 (4.6%)0.50Anticoagulant therapy–0/152 (4.6%)1.00Antiplatelet–12 (21.8%)7 (16.3%)0.21Haemoglobin g/L, median (range)130–160100.0 (73.0–149.0)96.3 (70.0–135.8)0.92Platelets ×109/L, median (range)150–400254 (69–545)130 (46–454)0.0002White blood -Abstract Truncated-

peripheral vascular disease,hematology